These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22579611)

  • 1. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2.
    Tsubaki M; Satou T; Itoh T; Imano M; Yanae M; Kato C; Takagoshi R; Komai M; Nishida S
    Mol Cell Endocrinol; 2012 Sep; 361(1-2):219-31. PubMed ID: 22579611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts.
    Persson E; Lerner UH
    J Cell Biochem; 2011 Dec; 112(12):3732-41. PubMed ID: 21815197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand.
    Wang QP; Yang L; Li XP; Xie H; Liao EY; Wang M; Luo XH
    Bone; 2012 Sep; 51(3):515-23. PubMed ID: 22634178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
    Yamada N; Tsujimura T; Ueda H; Hayashi S; Ohyama H; Okamura H; Terada N
    Cytokine; 2005 Aug; 31(4):288-97. PubMed ID: 15996478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.
    Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL
    J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.
    Kondo T; Kitazawa R; Yamaguchi A; Kitazawa S
    J Cell Biochem; 2008 Jan; 103(1):335-45. PubMed ID: 17516544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
    Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
    Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation.
    Tang CH; Chang CS; Tan TW; Liu SC; Liu JF
    Eur J Pharmacol; 2010 Dec; 648(1-3):59-66. PubMed ID: 20850430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.